CLINICAL TRIALS PROFILE FOR ERYTHROMYCIN AND BENZOYL PEROXIDE
✉ Email this page to a colleague
All Clinical Trials for ERYTHROMYCIN AND BENZOYL PEROXIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00823901 ↗ | Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea | Completed | Medicis Pharmaceutical Corporation | Phase 2/Phase 3 | 2009-02-01 | The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea. |
| NCT00823901 ↗ | Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea | Completed | Massachusetts General Hospital | Phase 2/Phase 3 | 2009-02-01 | The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea. |
| NCT01706263 ↗ | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne | Completed | GlaxoSmithKline | Phase 4 | 2009-08-01 | One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate the efficacy and tolerability of MAXCLARITY II, an over the counter, topical benzoyl peroxide (BPO) product line, in subjects with acne. |
| NCT01706263 ↗ | U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne | Completed | Stiefel, a GSK Company | Phase 4 | 2009-08-01 | One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate the efficacy and tolerability of MAXCLARITY II, an over the counter, topical benzoyl peroxide (BPO) product line, in subjects with acne. |
| NCT04000347 ↗ | A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor | Recruiting | Mahidol University | Phase 4 | 2019-06-26 | This study aimed to study the efficacy of topical 2.5% benzoyl peroxide, compared to 5% benzoyl peroxide in treatment of unpleasant foot odor, which was considered as major problem related to pitted keratolysis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ERYTHROMYCIN AND BENZOYL PEROXIDE
Condition Name
Clinical Trial Locations for ERYTHROMYCIN AND BENZOYL PEROXIDE
Trials by Country
Clinical Trial Progress for ERYTHROMYCIN AND BENZOYL PEROXIDE
Clinical Trial Phase
Clinical Trial Sponsors for ERYTHROMYCIN AND BENZOYL PEROXIDE
Sponsor Name
